Zenocutuzumab(一种HER2xHER3双特异性抗体)对NRG1基因重排驱动的肿瘤有效
NRG1重排是实体瘤中反复出现的致癌驱动因素,NRG1与HER3结合后与其它HER/ERBB激酶异二聚化并增强下游信号。研究在NRG1融合阳性同源细胞系和患者来源细胞系及异种移植模型中检测了抗体依赖性细胞毒性增强的抗HER2xHER3双特异性抗体zenocutuzumab(Zeno;MCLA-128),Zeno抑制HER3和AKT磷酸化、诱导凋亡标志物表达并抑制生长。3例化疗耐药的NRG1融合阳性转移性癌症患者接受Zeno治疗,其中2例ATP1B1-NRG1阳性胰腺癌患者获得快速症状、生物标志物和影像学缓解并持续治疗超过12个月,1例CD74-NRG1阳性非小细胞肺癌患者在接受包括阿法替尼在内的六线全身治疗后进展,接受Zeno治疗后快速获得部分缓解。
要点
- Zeno在NRG1融合阳性细胞系和异种移植模型中抑制HER3和AKT磷酸化、诱导凋亡标志物并抑制生长。
- 2例ATP1B1-NRG1阳性胰腺癌患者经Zeno治疗后获得快速症状、生物标志物和影像学缓解,持续治疗超过12个月。
- 1例CD74-NRG1阳性非小细胞肺癌患者在接受六线全身治疗(包括阿法替尼)后进展,经Zeno治疗快速获得部分缓解。
核心结论
- 同时靶向HER2和HER3的Zeno是NRG1融合阳性癌症患者的一种新型治疗范式。
- Zeno在NRG1融合阳性癌症患者中产生持久临床缓解,是一种有效的治疗策略。
研究设计与样本
- 研究在NRG1融合阳性同源细胞系和患者来源细胞系及异种移植模型中检测Zeno(MCLA-128),一种抗体依赖性细胞毒性增强的抗HER2xHER3双特异性抗体。
- 3例化疗耐药的NRG1融合阳性转移性癌症患者接受Zeno治疗。
主要发现
- Zeno抑制HER3和AKT磷酸化,诱导凋亡标志物表达并抑制生长。
- 2例ATP1B1-NRG1阳性胰腺癌患者获得快速症状、生物标志物和影像学缓解,并持续治疗超过12个月。
- 1例CD74-NRG1阳性非小细胞肺癌患者在接受包括阿法替尼在内的六线全身治疗后进展,接受Zeno治疗后快速获得部分缓解。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: NRG1 rearrangements are recurrent oncogenic drivers in solid tumors. NRG1 binds to HER3, leading to heterodimerization with other HER/ERBB kinases, increased downstream signaling, and tumorigenesis. Targeting ERBBs, therefore, represents a therapeutic strategy for these cancers. We investigated zenocutuzumab (Zeno; MCLA-128), an antibody-dependent cellular cytotoxicity-enhanced anti-HER2xHER3 bispecific antibody, in NRG1 fusion-positive isogenic and patient-derived cell lines and xenograft models. Zeno inhibited HER3 and AKT phosphorylation, induced expression of apoptosis markers, and inhibited growth. Three patients with chemotherapy-resistant NRG1 fusion-positive metastatic cancer were treated with Zeno. Two patients with ATP1B1-NRG1-positive pancreatic cancer achieved rapid symptomatic, biomarker, and radiographic responses and remained on treatment for over 12 months. A patient with CD74-NRG1-positive non-small cell lung cancer who had progressed on six prior lines of systemic therapy, including afatinib, responded rapidly to treatment with a partial response. Targeting HER2 and HER3 simultaneously with Zeno is a novel therapeutic paradigm for patients with NRG1 fusion-positive cancers. SIGNIFICANCE: NRG1 rearrangements encode chimeric ligands that activate the ERBB receptor tyrosine kinase family. Here we show that targeting HER2 and HER3 simultaneously with the bispecific antibody Zeno leads to durable clinical responses in patients with NRG1 fusion-positive cancers and is thus an effective therapeutic strategy. This article is highlighted in the In This Issue feature, p. 1171.
引用
- Schram AM, Odintsov I, Espinosa-Cotton M, et al. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discov. 2022. PMID: 35135829. doi:10.1158/2159-8290.CD-21-1119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。